Literature DB >> 25344526

Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients.

Cecilie Blimark1, Erik Holmberg2, Ulf-Henrik Mellqvist3, Ola Landgren4, Magnus Björkholm5, Malin Hultcrantz5, Christian Kjellander5, Ingemar Turesson6, Sigurdur Y Kristinsson7.   

Abstract

Infections are a major cause of morbidity and mortality in patients with multiple myeloma. To estimate the risk of bacterial and viral infections in multiple myeloma patients, we used population-based data from Sweden to identify all multiple myeloma patients (n=9253) diagnosed from 1988 to 2004 with follow up to 2007 and 34,931 matched controls. Cox proportional hazard models were used to estimate the risk of infections. Overall, multiple myeloma patients had a 7-fold (hazard ratio =7.1; 95% confidence interval = 6.8-7.4) risk of developing any infection compared to matched controls. The increased risk of developing a bacterial infection was 7-fold (7.1; 6.8-7.4), and for viral infections 10-fold (10.0; 8.9-11.4). Multiple myeloma patients diagnosed in the more recent calendar periods had significantly higher risk of infections compared to controls (P<0.001). At one year of follow up, infection was the underlying cause in 22% of deaths in multiple myeloma patients. Mortality due to infections remained constant during the study period. Our findings confirm that infections represent a major threat to multiple myeloma patients. The effect on infectious complications due to novel drugs introduced in the treatment of multiple myeloma needs to be established and trials on prophylactic measures are needed. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Year:  2014        PMID: 25344526      PMCID: PMC4281323          DOI: 10.3324/haematol.2014.107714

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  30 in total

Review 1.  Major complications following hematopoietic stem cell transplantation.

Authors:  Bekele Afessa; Steve G Peters
Journal:  Semin Respir Crit Care Med       Date:  2006-06       Impact factor: 3.119

2.  Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party.

Authors:  Bradley M Augustson; Gulnaz Begum; Janet A Dunn; Nicola J Barth; Faith Davies; Gareth Morgan; Judith Behrens; Alastair Smith; J Anthony Child; Mark T Drayson
Journal:  J Clin Oncol       Date:  2005-11-07       Impact factor: 44.544

3.  The risk of bacteremia in patients with monoclonal gammopathy of undetermined significance.

Authors:  H Gregersen; K M Madsen; H T Sørensen; H C Schønheyder; J S Ibsen; J F Dahlerup
Journal:  Eur J Haematol       Date:  1998-08       Impact factor: 2.997

Review 4.  Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents.

Authors:  Marcio Nucci; Elias Anaissie
Journal:  Clin Infect Dis       Date:  2009-10-15       Impact factor: 9.079

5.  Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.

Authors:  Ulf-Henrik Mellqvist; Stig Lenhoff; Hans E Johnsen; Martin Hjorth; Erik Holmberg; Gunnar Juliusson; Jon Magnus Tangen; Jan Westin
Journal:  Cancer       Date:  2008-01-01       Impact factor: 6.860

Review 6.  Immunodeficiency and immunotherapy in multiple myeloma.

Authors:  Guy Pratt; Oliver Goodyear; Paul Moss
Journal:  Br J Haematol       Date:  2007-09       Impact factor: 6.998

7.  Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003.

Authors:  Ingemar Turesson; Martha S Linet; Magnus Björkholm; Sigurdur Y Kristinsson; Lynn R Goldin; Neil E Caporaso; Ola Landgren
Journal:  Int J Cancer       Date:  2007-11-15       Impact factor: 7.396

8.  Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.

Authors:  Asher Chanan-Khan; Pieter Sonneveld; Michael W Schuster; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Rachel Neuwirth; Kenneth C Anderson; Paul G Richardson
Journal:  J Clin Oncol       Date:  2008-08-18       Impact factor: 44.544

9.  Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003.

Authors:  Sigurdur Yngvi Kristinsson; Ola Landgren; Paul W Dickman; Asa Rangert Derolf; Magnus Björkholm
Journal:  J Clin Oncol       Date:  2007-04-09       Impact factor: 44.544

10.  Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study.

Authors:  Ingemar Turesson; Ramon Velez; Sigurdur Y Kristinsson; Ola Landgren
Journal:  J Clin Oncol       Date:  2009-12-28       Impact factor: 44.544

View more
  119 in total

1.  Poor Correlation between Pneumococcal IgG and IgM Titers and Opsonophagocytic Activity in Vaccinated Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia.

Authors:  Johanna Karlsson; Lucy Roalfe; Harriet Hogevik; Marta Zancolli; Björn Andréasson; David Goldblatt; Christine Wennerås
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

2.  Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial.

Authors:  Andrew R Branagan; Eamon Duffy; Randy A Albrecht; Dennis L Cooper; Stuart Seropian; Terri L Parker; Geliang Gan; Fangyong Li; Daniel Zelterman; Chandra Sekhar Boddupalli; Lin Zhang; Rakesh Verma; Thomas M Ferencz; Madhav V Dhodapkar
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2017-03-07

Review 3.  ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).

Authors:  G Redelman-Sidi; O Michielin; C Cervera; C Ribi; J M Aguado; M Fernández-Ruiz; O Manuel
Journal:  Clin Microbiol Infect       Date:  2018-02-07       Impact factor: 8.067

4.  SARS-CoV-2 in multiple myeloma: initial observation and management.

Authors:  Elisabet E Manasanch; Victor Mulanovich; Joanna-Grace Manzano; Maria Susan Gaeta; Melody Becnel; Gregory P Kaufman; Hans C Lee; Behrang Amini; Sheeba K Thomas; Swaminathan P Iyer; Donna M Weber; Zuzana Berkova; Christopher R Flowers; Robert Z Orlowski; Krina K Patel
Journal:  Leuk Lymphoma       Date:  2020-06-17

5.  Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset.

Authors:  Ajai Chari; Mehmet Kemal Samur; Joaquin Martinez-Lopez; Gordon Cook; Noa Biran; Kwee L Yong; Vania Tietsche de Moraes Hungria; Monika Engelhardt; Francesca Gay; Ana Garcia-Feria; Stefania Oliva; Rimke Oostvogels; Alessandro Gozzetti; Cara A Rosenbaum; Shaji K Kumar; Edward Stadtmauer; Hermann Einsele; Meral Beksac; Katja C Weisel; Kenneth C Anderson; Maria-Victoria Mateos; Philippe Moreau; Jesús San Miguel; Nikhil C Munshi; Hervé Avet-Loiseau
Journal:  Blood       Date:  2020-11-06       Impact factor: 22.113

6.  European Myeloma Network guidelines for the management of multiple myeloma-related complications.

Authors:  Evangelos Terpos; Martina Kleber; Monika Engelhardt; Sonja Zweegman; Francesca Gay; Efstathios Kastritis; Niels W C J van de Donk; Benedetto Bruno; Orhan Sezer; Annemiek Broijl; Sara Bringhen; Meral Beksac; Alessandra Larocca; Roman Hajek; Pellegrino Musto; Hans Erik Johnsen; Fortunato Morabito; Heinz Ludwig; Michele Cavo; Hermann Einsele; Pieter Sonneveld; Meletios A Dimopoulos; Antonio Palumbo
Journal:  Haematologica       Date:  2015-10       Impact factor: 9.941

7.  Infectious complications in multiple myeloma receiving autologous stem cell transplantation in the past 10 years.

Authors:  Hyunkyung Park; Jeonghwan Youk; Hak Ro Kim; Youngil Koh; Ji Hyun Kwon; Sung-Soo Yoon; Seonyang Park; Pyoeng Gyun Choe; Nam Joong Kim; Myoung-Don Oh; Wan Beom Park; Inho Kim
Journal:  Int J Hematol       Date:  2017-08-20       Impact factor: 2.490

8.  Multiple Myeloma Baseline Immunoglobulin G Level and Pneumococcal Vaccination Antibody Response.

Authors:  Michael A Thompson; Martin K Oaks; Maharaj Singh; Karen M Michel; Michael P Mullane; Husam S Tarawneh; Angi Kraut; Kayla J Hamm
Journal:  J Patient Cent Res Rev       Date:  2017-08-10

Review 9.  Presentation of multiple myeloma occurring in the humerus after strain: a case report.

Authors:  Ebru Yilmaz
Journal:  Clin Rheumatol       Date:  2020-07-01       Impact factor: 2.980

10.  Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitors.

Authors:  Siyang Leng; Suzanne Lentzsch; Yanhan Shen; Wei-Yann Tsai; Jason Dennis Wright; Dawn Lauryn Hershman; Alfred I Neugut
Journal:  Leuk Lymphoma       Date:  2018-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.